Drug profile · INN
emedastine difumarate
EMADINE
emedastine difumarate (EMADINE) is a histamine h1 receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Drug details — emedastine difumarate
- US status
- approved
- Class
- —
- Route
- OPHTHALMIC
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
emedastine difumarate (EMADINE) is a histamine h1 receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
Key facts
Mechanism of action
Histamine H1 receptor antagonist
Primary target: Histamine H1 receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is emedastine difumarate?
emedastine difumarate (EMADINE) is a histamine h1 receptor antagonist. Route of administration: ophthalmic. Current US regulatory status: approved.
What is the brand name for emedastine difumarate?
EMADINE is a marketed brand name for emedastine difumarate. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of emedastine difumarate?
emedastine difumarate has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.